市場調査レポート

商品コード

1085791

急性外陰膣カンジダ症治療の世界市場：薬物タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月22日 | 発行: Coherent Market Insights

| ページ情報: 英文 152 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 704,385円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,095,710円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,565,300円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.53円

全表示
概要
目次

概要

サンプル依頼リストに入れる

市場企業は、製品ポートフォリオの拡大、世界市場での地位強化、予測期間中の世界市場の成長促進が期待される買収などの無機的な活動に専念しています。また、外陰膣カンジダ症治療開発のための研究開発の増加が、予測期間中、世界の急性外陰膣カンジダ症治療市場の成長を促進すると予測されます。

当レポートでは、世界の急性外陰膣カンジダ症治療市場について調査分析し、市場概要、市場力学、動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

企業プロファイル
- Mycovia Pharmaceuticals, Inc.
- Scynexis, Inc.
- Basilea Pharmaceutica Ltd.
- Astellas Pharma Inc.
- Grupo Ferrer Internacional, SA
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc
- Amplyx Pharmaceuticals Inc.,
- Pfizer, Inc.
アナリストの見解

第10章セクション

Product Code: CMI4315

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2022, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-γ, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study:

This report provides an in-depth analysis of global acute vulvovaginal candidiasis treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Detailed Segmentation:

Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
- Oral
- Intravenous
- Topical
Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
- North America
By Country
- U.S.
- Canada
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
By Country:
- GCC
- Israel
- Rest of Middle East
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
By Country/Region:
- South Africa
- Central Africa
- North Africa
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
Mycovia Pharmaceuticals, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Scynexis, Inc.
Basilea Pharmaceutica Ltd.
Astellas Pharma Inc.
Grupo Ferrer Internacional, S.A.
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Amplyx Pharmaceuticals Inc.
Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Key Developments
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Market Share Analysis
Brand Analysis

4. Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus COVID - 19 Impact

During COVID-19 Market Situation
Supply Side and Demand Side Analysis
Impact of COVID-19 on Acute Vulvovaginal Candidiasis Treatment Market
Government Initiatives to Combat COVID-19

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Clotrimazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nystatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Ketoconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Terbinafine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Terconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Company Profiles
- Mycovia Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Scynexis, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Grupo Ferrer Internacional, S.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pacgen Life Science Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- NovaDigm Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Cidara Therapeutics, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Amplyx Pharmaceuticals Inc.,
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact

急性外陰膣カンジダ症治療の世界市場：薬物タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界の急性外陰膣カンジダ症治療市場：コロナウイルスCOVID-19パンデミックの影響

第5章世界の急性外陰膣カンジダ症治療市場：薬剤タイプ別（2017年～2028年）

第6章世界の急性外陰膣カンジダ症治療市場：投与経路別（2017年～2028年）

第7章世界の急性外陰膣カンジダ症治療市場：流通チャネル別（2017年～2028年）

第8章世界の急性外陰膣カンジダ症治療市場：地域別（2017年～2028年）

第9章競合情勢

第10章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus COVID - 19 Impact

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2017 - 2028 (US$ Million)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2017 - 2028 (US$ Million)

9. Competitive Landscape

10. Section

急性外陰膣カンジダ症治療の世界市場：薬物タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

第4章 世界の急性外陰膣カンジダ症治療市場：コロナウイルスCOVID-19パンデミックの影響

第5章 世界の急性外陰膣カンジダ症治療市場：薬剤タイプ別（2017年～2028年）

第6章 世界の急性外陰膣カンジダ症治療市場：投与経路別（2017年～2028年）

第7章 世界の急性外陰膣カンジダ症治療市場：流通チャネル別（2017年～2028年）

第8章 世界の急性外陰膣カンジダ症治療市場：地域別（2017年～2028年）

第9章 競合情勢

第10章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus COVID - 19 Impact

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2017 - 2028 (US$ Million)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2017 - 2028 (US$ Million)

9. Competitive Landscape

10. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界の急性外陰膣カンジダ症治療市場：コロナウイルスCOVID-19パンデミックの影響

第5章世界の急性外陰膣カンジダ症治療市場：薬剤タイプ別（2017年～2028年）

第6章世界の急性外陰膣カンジダ症治療市場：投与経路別（2017年～2028年）

第7章世界の急性外陰膣カンジダ症治療市場：流通チャネル別（2017年～2028年）

第8章世界の急性外陰膣カンジダ症治療市場：地域別（2017年～2028年）

第9章競合情勢

第10章セクション